Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QBR202
- Development stage
- Phase 1
- Lead developer
- Xunji Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
QBR202 is a long-acting biologic agent designed to inhibit vascular endothelial growth factor (VEGF), currently under development by Beijing Xunji Biotechnology for the treatment of retinal vascular disorders. The drug is primarily indicated for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). By targeting and neutralizing VEGF-A, QBR202 aims to suppress the pathological angiogenesis and vascular permeability that drive vision loss in these conditions. It is administered via intravitreal injection and is currently being evaluated in Phase I clinical trials in China to assess its safety, tolerability, and preliminary efficacy.
02
Targets
Beyond the preview
Go deeper on QBR202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QBR202.